In this study, the authors developed HEK293 cell lines that stably coexpressed optimal amounts of β-arrestin2-Rluc and VENUS fusions of G protein-coupled receptors (GPCRs) belonging to both class A and class B receptors, which include receptors that interact transiently or stably with β-arrestins. This allowed the use of a bioluminescence resonance energy transfer (BRET) 1-β-arrestin2 translocation assay to quantify receptor activation or inhibition. One of the developed cell lines coexpressing CCR5-VENUS and β-arrestin2-Renilla luciferase was then used for high-throughput screening (HTS) for antagonists of the chemokine receptor CCR5, the primary co-receptor for HIV. A total of 26,000 compounds were screened for inhibition of the agonist-promoted β-arrestin2 recruitment to CCR5, and 12 compounds were found to specifically inhibit the agonist-induced β-arrestin2 recruitment to CCR5. Three of the potential hits were further tested using other functional assays, and their abilities to inhibit CCR5 agonist-promoted signaling were confirmed. This is the 1st study describing a BRET1-βarrestin recruitment assay in stable mammalian cells and its successful application in HTS for GPCRs antagonists. (Journal of Biomolecular Screening 2005:463-475) 
G PROTEIN-COUPLED RECEPTORS (GPCRs) are heptahelical receptors that constitute the largest family of cell surface proteins involved in signal transduction. In humans, it is estimated that GPCRs are encoded by~750 distinct genes that control a variety of important physiological functions, including vision, olfaction, taste, neurotransmission, chemoattraction, inflammation, growth, and cellular metabolism. 1 Because of their diverse actions and because their dysfunctions have been often associated with critical diseases (e.g., heart diseases, asthma, mental and metabolic disorders), GPCRs represent a very important target for chemotherapeutic intervention. 2 In fact, approximately 30% of the marketed drugs act either directly or indirectly on GPCRs. 3 Therefore, the development of sensitive, versatile, and low-cost highthroughput screening (HTS) assays that monitor GPCR activity is of continuous interest for drug discovery. In addition, recent recognition of the diversity of signaling modes of GPCRs 4 justifies the development of multiple screening assays that target different signaling pathways.
Upon agonist activation, GPCRs undergo conformational changes that favor their interaction with G proteins, leading to the activation of various intracellular effectors. Termination of GPCR signaling is tightly controlled and is achieved, in part, by receptor binding to intracellular adaptor proteins known as arrestins. To date, 4 types of arrestin genes have been isolated from mammals, 2 being visual arrestins (arrestin1 and 4) that are expressed in rods and cons, where they mediate the desensitization of photoreceptors. 5 Nonvisual arrestin2 and 3 (also known as β-arrestin1 and β-arrestin2) are ubiquitously expressed and have been shown to interact with most GPCRs (for recent reviews, see Gurevich and Gurevich 5 and Shenoy and Lefkowitz 6 ). For the majority of GPCRs, agonist activation leads to receptor phosphorylation by specific G protein receptor kinases and the subsequent recruitment of the adaptor protein β-arrestin to the receptor, an event that results in the uncoupling of the receptor from its cognate G protein and the movement of the β-arrestin-receptor complex toward preformed clathrin pits for endocytosis, after which GPCRs are either recycled to the cell surface or degraded in the lyzosomes. 7, 8 Based on immunofluorescence studies and realtime imaging of the interaction between various receptors and βarrestins fused to green fluorescent protein (GFP), GPCRs are di-vided into 2 classes, A and B. Class A receptors bind with higher affinity to β-arrestin2 than to β-arrestin1; however, this association is unstable, and β-arrestins rapidly dissociate from the receptor near or at the plasma membrane without internalizing with it. 9, 10 In contrast to class A receptors, class B receptors bind both βarrestins with similar high affinities and the receptor-β-arrestin complex internalizes as a unit. 9, 10 Several molecular determinants of β-arrestin interaction sites have been identified in GPCRs, including phosphorylation sites at the C-terminus (clusters of serine and/or threonins) 11 and stretches of basic amino acids at the boundaries of the 3rd intracellular loop, 12 as well as the conserved "DRY" motif in the 2nd intracellular loop. 13 In 2000, Angers et al. first reported the use of a new cell-based biophysical technique named bioluminescence resonance energy transfer (BRET) 14 to monitor and quantify agonist-promoted β-arrestin2 recruitment to the β2-adrenergic receptor in living cells. 15 This provided a new proteomic assay to study GPCR activation, which, unlike other cell-based assays (e.g., intracellular Ca ++ release or cAMP accumulation), is not dependent on the preference of the receptor for specific G proteins (G q/11 , G s , G i/o ; reviewed by Heding 16 ). It is important to note here that there exist also few GPCRs that are suggested to internalize via β-arrestin independent pathways 17 or that do not internalize at all, at least in some cultured cells (e.g., GABA B receptors, β3-adrenergic receptors), 18, 19 and therefore, functional assays relying on β-arrestin translocation are not suitable for these receptors.
BRET, a derivative of fluorescence resonance energy transfer, is based on the nonradiative energy transfer between the electromagnetic dipoles of an energy donor and that of an energy acceptor. This transfer of energy from a luminescent donor to a fluorescent acceptor is known as BRET (recently reviewed by Milligan 20 and Pfleger and Eidne 21 ). For resonance energy transfer to occur, the emission spectrum of the energy donor should overlap with the absorption spectrum of the energy acceptor, and both proteins should be within less than 100 Å and in favorable orientation. To study the interaction between 2 proteins using the 1st-generation BRET (BRET1), one protein is fused to the energy donor Renilla luciferase (Rluc) and the other is fused to the energy acceptor EYFP. Upon catalytic degradation of the cell-permeable substrate coelenterazine by Rluc, light is emitted (peak~480 nm), which is sufficiently broad in spectrum to excite an adjacent EYFP that in turn emits light at its characteristic wavelength (peak~530 nm). The resulting BRET signal is represented as a ratiometric reading of the emission of EYFP/Rluc. 14, 15 A modified version of BRET1, termed BRET2, uses a mutant GFP (GFP2: excitation 400 nm, emission 511 nm) as the energy acceptor and a modified substrate known as DeepBlueC that shifts the maximal emission of Rluc from 480 nm to 400 nm. Currently, both BRET versions are being used for studying protein-protein interactions, including monitoring of GPCR activation by BRET-based βarrestin recruitment assays. 15, [22] [23] [24] [25] [26] [27] [28] [29] In this study, we report the development of an optimized BRET1-based β-arrestin2 assay for several GPCRs belonging to class A and class B receptors. Unlike most of the previous BRET-based β-arrestin studies that relied on the transient coexpression of the receptor and β-arrestin, the current work employed double stable cell lines that constitutively expressed optimal levels of both β-arrestin2-Rluc and GPCRs fused to a modified EYFP (VENUS), providing a robust and a mainstreamed platform for HTS of GPCR ligands. As a proof of principle, the developed CCR5/β-arrestin2 "BRET-ready" cell line was used for HTS of 26,000 small molecule compounds for antagonistic activity against the CC chemokine receptor CCR5, the primary co-receptor for HIV-1. 30 This is the 1st study to report a BRET1-based β-arrestin HTS in stably transfected mammalian cells and should be of general application to all GPCRs that can recruit β-arrestins. 
MATERIALS AND METHODS

Materials
Expression plasmids
The constructs presented herein were made using standard molecular biology techniques employing PCR and fragment replacement strategies. All generated constructs were verified by DNA sequencing. To make hRluc-EYFP, hRluc-GFP2, and hRluc-VENUS fusion plasmids, the coding sequences of EYFP, GFP2, and VENUS 31 were PCR amplified from plasmid templates and cloned in-frame with the C-terminus of a humanized Rluc (hRluc encoded by phRluc-C3) via a 26-amino-acid linker (GDLASSREFSRVCRISGARSVLKLGA). To construct the β-arrestin2-Rluc plasmid, the complete coding sequence of the rat β-arrestin2 was PCR amplified without its stop codon and then fused in-frame to the coding sequence of Rluc (amplified from pRluc) via a 7-amino-acid linker (GAGALAT) and ligated to the mammalian expression vector pcDNA3.1z(+). The coding sequences of the human GPCRs used in this study were PCR amplified without their stop codons from plasmid templates, fused at their C-termini with the coding sequence of VENUS via a flexible linker (GGGGS), and ligated into the mammalian expression vector pIRESpuro3. These GPCRs included the vasopressin V2 and V1a receptors (V2R, V1aR), the platelet activating factor receptor (PAF-R), β2-adrenergic receptor (β2AR), and CCR5 and CXCR4 receptors. The CXCR4-R5ctail-VENUS chimera was made by replacing the C-tail of CXCR4 (amino acids positions 333-375) with the corresponding sequence from the C-tail of CCR5 without its stop codon (amino acids 329-376), followed by an in-frame fusion to VENUS (via a linker sequence: GVPVNSGGGGS) and ligation to the vector pIRESpuro3.
Cell culture, plasmid transfections, and stable cell line generation
Human embryonic kidney (HEK) 293 and HEK293T were cultured in high-glucose DMEM supplemented with 5% FBS, 100 U/ ml penicillin-streptomycin, and 2 mM L-glutamine at 37°C in a humidified chamber at 95% air and 5% CO 2 . For transient expression of recombinant proteins, 6-well plates were seeded with 350,000 HEK293T cells. Approximately 18 h later, the cells were transfected using Lipofectamine2000 according to the manufacturer's recommendations. To generate cells stably expressing β-arrestin2-Rluc, HEK293 cells were transfected in 100-mm dishes, and 24 h posttransfection, the cells were trypsinized and diluted 1:50 to 1:500 and then seeded into 100-mm dishes in a culture medium containing 25 µg/ml Zeocin. After 2 weeks of Zeocin treatment, individual resistant foci were isolated and expanded, and the relative expression levels of β-arrestin2-Rluc from each clonal cell line were quantified by measuring total luminescence emitted by the Rluc as described below. To generate polyclonal cells coexpressing β-arrestin2-Rluc and receptor-VENUS, HEK293 cells stably expressing optimal levels of β-arrestin2-Rluc were transfected in 100-mm dishes with the bicistronic expression vector pIRESpuro3 encoding GPCR-VENUS fusions. Twenty-four hours posttransfection, the culture medium was removed and replaced with medium containing 1 µg/ml puromycin. After approximately 10 days of puromycin selection, polyclonal populations of double stable cell lines were obtained. The polyclonal population of each receptor-VENUS/β-arrestin2-Rluc cells was then subjected to fluorescence-assisted cell sorting whereby a total of 150,000 to 200,000 homogeneously fluorescent cells (indicative of similar GPCR-VENUS expression levels) were sorted and expanded for use.
Luminescence and fluorescence measurements
To measure total luminescence and fluorescence, cells were washed once with phosphate-buffered saline (PBS; KCl, 2.7 mM; KH 2 PO 4 , 1.1 mM; NaCl, 138 mM; Na 2 HPO 4 , 8.1 mM; MgCl 2 , 0.5 mM, pH 7.4), gently detached by pippeting in PBS containing 0.1% glucose and seeded at a density of~50,000 to 100,000 cells in 96-well white opaque plates (luminescence measurement) or white-wall with clear-bottom plates (fluorescence measurement). Throughout this study, cell number quantification was based on measuring the OD600 of the cell suspension and correlating it to a preestablished standard curve (OD600 vs. cell number). Luminescence was measured on the Mithras LB940 plate reader after the addition of the Rluc substrates (final concentration 5 µM) coelenterazine-h or DeepBlueC. Fluorescence measurements were taken also on the Mithras LB940 (excitation 480 nm, emission 535 nm).
BRET assays on cells in suspension
For BRET1 measurements, cells grown as a monolayer were washed once with PBS, detached by gentle pipetting in PBS supplemented with 0.1% D-glucose, and dispensed into 96-well white opaque plates at a density of~50,000 cells/well (unless indicated otherwise). Coelenterazine-h was then added (10 µl to 90-µl cell suspension volume) to a final concentration of 5 µM, and the BRET1 signal was measured on the FUSION or the Mithras LB940 plate readers that allow sequential integration of signals detected in 440 to 500 nm and 510 to 590 nm. The BRET1 ratio was calculated as emission at 510 to 590 nm/emission at 440 to 500 nm. The BRET1net is defined as the BRET1 ratio of cells coexpressing Rluc and EYFP or VENUS constructs minus the BRET1 ratio of cells expressing only the Rluc construct in the same experiment. For BRET2 measurements, cells were processed as for BRET1 and measured on the Mithras LB940 after the addition of DeepBlueC (5 µM final concentration). The BRET2 ratio was determined as emission at 515 ± 20 nm/400 ±70 nm. The BRET2net = BRET2 ratio of cells coexpressing Rluc and GFP2 constructs minus the BRET2 ratio of cells expressing only the Rluc in the same experiment. For the BRET1-β-arrestin2 recruitment assays, cells coexpressing β-arrestin2-Rluc and GPCR-VENUS were detached as above, and agonists were added for the specified period of time followed by the addition of coelenterazine-h and BRET1 measurements on the FUSION plate reader. In case of kinetic analysis, coelenterazine-h and the agonists were added simultaneously, and the BRET1 signal was measured over time. Agonist-promoted BRET1 is calculated as BRET1 ratio after agonist stimulation minus the BRET1 ratio of the same cells in the absence of the agonist used. The agonists used herein were SDF1α (for CXCR4), RANTES (for CCR5), AVP (for V2R and V1aR), and BRET1-Based -Arrestin2 Recruitment Assay isoproterenol (for β2AR). To measure antagonist inhibition of the agonist-promoted β-arrestin recruitment, cells coexpressing β-arrestin2-Rluc and GPCR-VENUS were processed as above and preincubated at room temperature for 5 to 10 min with the test antagonists at the indicated concentrations, followed by the addition of the agonist and incubation for the specified time prior to BRET1 measurements. The antagonists used herein were AMD3100 (specific for CXCR4), 32 TAK-799 (specific for CCR5), 33 SR121463A (specific for V2R), 34 PhAc-AVP (for V1aR), 35 and pindolol (for β2AR). Apparent inhibition constants were calculated from the EC 50 of RANTES and the IC 50 of test compound using the PRISM4 software (GraphPad).
BRET1-based β-arrestin HTS of CCR5 antagonists
The compound collection used for HTS was constituted of 24,320 synthetic small molecules from ChemBridge and 1680 synthetic and natural products from MicroSource Discovery. Each 96-well plate contained 80 discrete compounds dissolved in DMSO (columns 2-11; columns 1 and 12 contained only DMSO). Cells stably coexpressing β-arrestin2-Rluc and CCR5-VENUS were seeded in 96-well tissue culture white opaque plates at a density of 15,000 cells/well. The next day, the medium was removed by aspiration and 90 µl of PBS was gently added to each well. Test compounds (10-mM stocks) were dispensed (0.25 µl of each compound at a 25 µM final concentration; 2 compounds/well) into the assay plate using a liquid handling station equipped with a 96-well pin tool (Biomek FXII; Beckman Coulter, ON, Canada), followed by the addition of 10 µl of the CCR5 agonist RANTES (10 nM final concentration) to columns 2 to 12 (column 1 received 10 µl PBS). Agonist addition was done using a 96/384 plate liquid dispenser (Multidrop384 TiterTek; Huntsville, AL). After 30-min incubation at room temperature, 10 µl of coelenterazine-h (5 µM final) was added to all 96 wells, and the BRET1 ratio was measured on the BMG FluoStar Optra plate reader, as described above for the FUSION plate reader. Agonist-promoted BRET was measured as BRET ratio from columns 2 to 12 minus BRET ratio from column 1 (contained compound vehicle only). To facilitate data interpretation, the average agonist-promoted BRET1 signal obtained from column 12 (agonist alone) was normalized to 1 (100%), and the agonist-promoted BRET1 signal obtained in the presence of both agonist and test compounds was presented as a percentage of that obtained by the agonist alone. Only compounds that inhibited the agonist-promoted BRET signal by at least 50% and amounting to more than 3 standard deviations of the signal obtained in the presence of the agonist alone were considered as potential hits. To confirm primary hits, compounds showing inhibition were "cherrypicked" and dispensed into 96-well plates at a concentration of 2 mM and assayed, as described for the primary screen, at a final concentration of 10 µM. To test the specificity of the confirmed hits, a counterscreen was set using the HEK293 cells stably coexpressing β-arrestin2-Rluc and V2R-VENUS, in parallel with the CCR5 cell line used in the HTS; hit compounds were tested for their ability to inhibit the AVP (2 nM final concentration) promoted β-arrestin2-Rluc recruitment to V2R-VENUS, as measured by BRET1.
Intracellular calcium flux measurements
Calcium measurements were carried using the Calcium3 kit (Molecular Devices, Sunnyvale, CA) with minor modifications to the manufacturer's protocol. Briefly, HEK293 cells expressing CCR5-VENUS were seeded at 80,000 cells/well into poly-Dlysine-coated (0.1%) 96-well black-wall, clear-bottom plates. The next day, the culture medium was aspirated and replaced with 150 µl of Hanks balanced salt solution containing the Calcium3 reagent dye, followed by an incubation for 1 h at 37°C. Compound transfer and calcium measurements were done in the FLEXSTATION II plate reader (Molecular Devices, Sunnyvale, CA) preset to 37°C. Fluorescence readings (excitation 480 nm, emission 525 nm) were collected every 2 s for a total of 180 s. Fluorescence baseline determination was measured for the first 20 s, followed by injecting test compounds (25 µl) or the test compounds vehicle and fluorescence readings for another 35 s, after which the agonist RANTES (25 µl) was injected and fluorescence readings were continued for another 125 s. Test compounds and RANTES were used at final concentrations of 10 µM and 10 nM, respectively. An increase in fluorescence counts corresponded to an increase in intracellular calcium release. Calcium changes in response to compound/agonist additions were determined using a maximum minus minimum calculation of the raw fluorescence counts, and the data were represented as a percentage of the response obtained in the presence of the agonist RANTES alone.
RESULTS AND DISCUSSION
Choice of BRET assay for HTS
Currently, there are 2 versions of the BRET assay. BRET1 uses Rluc as an energy donor, EYFP (maximal excitation/emission: 511/530 nm) as an energy acceptor, and coelenterazine-h as a substrate for Rluc (maximal emission~480 nm). 14, 15 BRET2 differs from BRET1 by the use of a modified substrate for Rluc, DeepBlueC (emission of Rluc~400 nm), and a mutant form of GFP (GFP2, maximal excitation/emission: 400/510 nm). 25, 36, 37 Compared to BRET1, BRET2 has the advantage of an increased separation between the emission of Rluc and that of GFP2 (110 for BRET2 vs. 50 for BRET1), resulting in a lower background. On the other hand, a major disadvantage of BRET2 is that the luminescence emitted by Rluc upon catalyzing DeepBlueC is much less than its emission when coenterazine-h is used as a substrate. Figure  1A (see inset) shows the total luminescence emitted upon the catalysis of coelenterazine-h and DeepBlueC in the same cells expressing Rluc. The luminescence emitted by Rluc using coelenterazineh as a substrate was~300-fold higher than that obtained when DeepBlueC was used. In addition, the kinetics of the luminescence signal decay was significantly slower using coelenterazine-h than for DeepBlueC (t½~3 min for coelenterazine-h vs.~1 min for DeepBlueC; Fig. 1A ). It is important to note here that because the assay is ratiometric, a decrease in luminescence would not affect the BRET signal, provided that the luminescence signal does not drop below the sensitivity of the detector used. The reduced quantum yield of DeepBlueC combined with the fast decline of its luminescence requires the use of highly sensitive instrumentation for successful BRET2 measurements. In addition, more cells need to be seeded per well for BRET2 than for BRET1 to achieve luminescence levels suitable for BRET applications. This is shown in Figure 1B , in which BRET1 and BRET2 signals were measured from cells expressing similar levels of hRluc-EYFP and hRluc-GFP2 fusion constructs (as determined by total luminescence measurements using coelenterazine-h; see the inset of from 50,000 to 100,000 cells/well but started to nonspecifically increase (due to a significant drop in luminescence below the machine's sensitivity) when less than 50,000 cells were seeded per well. In contrast, the BRET1 signal obtained upon the addition of coelenterazine-h to cells expressing the hRluc-EYFP fusion was stable over a wide concentration of cells (1000-100,000 cells). Moreover, considering the time needed to read a full 96-well plate in BRET mode (~4-5 min), BRET2 measurements done using all 96 wells in the plate would not be possible unless the substrate were injected into each well followed by BRET2 measurement after a delay of few seconds, 38 which would significantly increase the reading time per plate (up to 15 min/plate). This longer reading time is disadvantageous for HTS, especially in cases in which only 1 plate reader is available. In contrast, for BRET1 applications, the substrate could be rapidly added to all the wells in the 96-well (or 384-well) plate followed by the BRET1 measurement of the entire plate, without risking a luminescence signal drop beyond the machine's detection sensitivity. In fact, catalysis of coelenterazine-h by Rluc emits enough luminescence to allow sensitive BRET1 signal measurement for at least 30 min after substrate addition (see the section below on the kinetics of β-arrestin2 recruitment and figures therein). Because of these problems associated with the use of DeepBlueC (low quantum yield, rapid luminescence decay, the need to inject the substrate), we concluded that BRET1 was a more appropriate platform for BRET-based HTS.
Choice of energy acceptor for BRET1
Previous studies using BRET1 have mainly used EYFP as an energy acceptor for Rluc. Recently, a mutated form of EYFP (F46L/F64L/M153T/V163A/S175G), named VENUS, was reported to mature faster and fluoresce better than the original EYFP while retaining the same spectral properties. In addition, VENUS displayed decreased sensitivity to acidic pH and chloride ions. 31 To test VENUS as a potential energy acceptor for Rluc in BRET1 and compare it to the original EYFP, fusion constructs between hRluc and EYFP and hRluc and VENUS were made such that both EYFP and VENUS were fused to hRluc via exactly the same amino acid linker, and therefore are likely to be separated from Rluc by the same distance corresponding to that of the linker used. The BRET1 signal obtained from the hRluc-VENUS fusion was 15% higher than that obtained from the hRluc-EYFP fusion, both being tested under identical conditions (Fig. 1C ). This indicated that VENUS served as a better energy acceptor for Rluc in BRET1, probably due to its higher extinction coefficient. 31 Based on its improved folding/maturation and enhanced energy transfer properties, we chose VENUS as the energy acceptor in subsequent BRET1 applications reported herein.
Development of β-arrestin2-Rluc/GPCR-VENUS stable cells
Most of the previously reported BRET-based β-arrestin recruitment assays were done on cells transiently cotransfected with βarrestin and GPCRs that had been fused to Rluc and GFP or EYFP.
Although the assay works well in a transient expression system, it is not practical for large HTS campaigns. Therefore, we sought to develop a system in which both β-arrestin2 and the GPCR are stably coexpressed at constitutive optimal levels in HEK293 cells, thus facilitating its use for HTS. We used β-arrestin2 because it interacts well with high affinity with both class A and class B receptors, in contrast to β-arrestin1, which has lower affinity for class A receptors. 10 First we developed clonal HEK293 cell lines that expressed different levels of β-arrestin2 fused at its C-terminus to Rluc (β-arrestin2-Rluc; Fig. 2A ). Then, to select the cell clone that expresses optimal Rluc levels for β-arrestin recruitment assays, we transiently transfected the various β-arrestin2-Rluc clones with equal amounts of a plasmid encoding the V2 vasopressin receptor (V2R) fused at its C-terminus to the energy acceptor VENUS (V2R-VENUS) and measured the agonist-promoted BRET signal indicative of the recruitment of β-arrestin2-Rluc to the receptor. Clonal cell line I displayed the highest BRET signal in response to stimulation with the V2R agonist, AVP, for 20 min, indicating that its β-arrestin2-Rluc expression level was the most suitable for BRET-β-arrestin2 recruitment assays (Fig. 2B ). In general, lower expression levels of β-arrestin2-Rluc resulted in higher agonistpromoted BRET because this ensured that most of the energy donor (Rluc) was engaged in BRET with the agonist-activated V2-VENUS protein (Fig. 2B ). However, clones expressing very little luciferase (such as D, F, H) failed to produce agonist-promoted BRET, indicating that the amount of β-arrestin2-Rluc was not sufficient for BRET detection. To generate cells stably coexpressing both β-arrestin2-Rluc and receptor-VENUS, we used clone I as a parent cell line in which we integrated the various receptor-VE-NUS constructs. The GPCRs that were used in this study belong to both class A (β2AR, V1aR) and class B (V2R, PAF-R, CCR5, CXCR4) receptors. 10, [39] [40] [41] [42] Previous reports have shown that fusing the C-termini of the GPCRs used in this study with GFP (or EYFP) did not alter their function compared to wild-type receptors. 15, 28, 40, 43, 44 We expressed the receptor-VENUS proteins from a bicistronic vector, such that both the receptor-VENUS and the resistance selection gene puromycin were translated from the same mRNA; this allowed the rapid creation of polyclonal cells stably expressing homogeneous levels of receptor-VENUS proteins. In general, it took an average of 10 days of selection with puromycin to generate the polyclonal cell lines, which were then subjected to fluorescence-assisted cell sorting to select cells expressing similar levels of receptor-VENUS proteins.
Monitoring receptor activity by a BRET1-␤-arrestin2 recruitment assay in stable cells
The developed BRET-ready cell lines described above were then validated for monitoring receptor activity. Agonist activation of class A receptors resulted in a rapid increase in agonistpromoted BRET, which peaked at~5 min (V1aR) to 10 min (β2AR) and then gradually declined over time, as expected of class A receptors that transiently interact with β-arrestins (Fig. 3A) . 10 On the other hand, agonist activation of class B receptors (V2R, CCR5, and PAF-R) induced a robust BRET signal that peaked at 10 to 15 min and remained constant over a period of at least 30 min, indicative of a prolonged association between β-arrestin and the receptor (Fig. 3A) . In addition, the amplitude of the agonistpromoted BRET signal obtained with class B receptors was~2-to 4-fold higher than that obtained with class A receptors, an effect that could also be explained by the fact that the interaction of βarrestins with class B receptors is more stable than that with class A receptors. Another possibility is that the interaction of β-arrestin2 with class B receptors favors optimal distance/orientation between the energy acceptor and the donor, leading to a larger BRET signal than that seen with class A receptors.
To demonstrate the utility of the established double stable BRET-ready cells for monitoring GPCR activity, we measured the BRET-β-arrestin2 recruitment in response to an increasing concentration of agonists specific to each receptor (Fig. 3B ). For class A receptors, agonist-promoted BRET was measured at the time needed to achieve maximum BRET signal (i.e., time-to-peak BRET signal after agonist addition: 5 min for V1aR, 15 min for β2R), whereas for class B receptors (V2R, PAF-R, CCR5, CXCR4), which stably interact with β-arrestins, the agonistpromoted BRET was measured at a time at which the BRET signal is at its plateau (greater than time-to-peak signal: 30 min postagonist addition). The EC 50 s obtained under these conditions for each agonist were in agreement with values reported in previous studies using other functional assays ( Table 1 ). The β-arrestin2 recruitment signal was detected only when the receptors were challenged with their specific agonists, and no agonist-promoted BRET was detected when irrelevant agonists were used (e.g., challenging the CCR5 cell line with AVP, SDF1α, isoproterenol, or c-PAF; data not shown).
Although agonist activation of CXCR4 has been shown to recruit β-arrestin2 in a manner consistent with class B receptors, 42 agonist stimulation of cells stably coexpressing CXCR4-VENUS and β-arrestin-2-Rluc resulted in a very low BRET signal with a limited signal-to-noise ratio (Fig. 3C ). This is in contrast to the robust BRET β-arrestin signal obtained with cells coexpressing β-arrestin2-Rluc and other class B receptors used herein (CCR5, V2R, PAF-R; Fig. 3B ). Because β-arrestin2 has been shown to interact with the C-tails of CXCR4 and CCR5, 42, 45, 46 we speculated that replacing the C-tail of CXCR4 with that of CCR5, a strong recruiter of β-arrestin2, could increase the level of the agonist promoted BRET-β-arrestin2 recruitment signal to the chimeric CXCR4 receptor (CXCR4-R5ctail). The CXCR4-R5ctail was engineered such that the amino acids after the end of transmembrane domain 7 from CCR5, which contain a palmitoylation site, replaced the corresponding region in the CXCR4 C-tail. Such a chimera was previously generated and was found to decrease the rate of receptor internalization without affecting its signaling properties. 47, 48 As shown in Figure 3C , agonist activation of HEK293 cells stably coexpressing CXCR4-R5ctail-VENUS and β-arrestin2-Rluc resulted in a robust BRET signal that is~3.5-fold higher than that obtained with cells stably coexpressing similar levels of CXCR4-VENUS/β-arrestin2-Rluc. No BRET signal was detected when the cells expressing CXCR4-R5ctail-VENUS/β-arrestin2-Rluc were challenged with the CCR5 receptor agonist RANTES, indicating that the CXCR4-R5ctail chimera retained specificity for CXCR4 ligands (data not shown). The EC 50 of SDF1α promoted β-arrestin2-Rluc recruitment to CXCR4-R5ctail-VENUS was calculated to be~4 nM, which is in agreement with what had been reported previously for wild-type CXCR4 using other functional assays ( Table 1 ). The increase in agonist-promoted BRET-β-arrestin2 recruitment observed with the chimeric CXCR4-R5ctail receptor, as compared to CXCR4, could be due to a higher affinity interaction between -arrestin2 and the C-tail of CCR5 (versus C-tail of CXCR4) or due to a more favorable orientation of the C-terminal VENUS fusion. The latter situation is very likely because, unlike CXCR4, CCR5 contains a palmitoylation site at its C-tail that anchors it to the plasma membrane 45, 49, 50 ; therefore, the orientation of the membrane anchored C-tail of CCR5 is expected to be different than that of the loose Ctail of CXCR4 and consequently may significantly influence the BRET signal of the β-arrestin2 recruitment assay. This is in agreement with the findings of Charest et al., 29 who showed reduced β-arrestin2 recruitment to a V2R mutant lacking its palmitoylation site compared to the wild-type V2R.
To test the suitability of using the established cell lines to screen for receptor antagonists, BRET-β-arrestin recruitment assays were done in the presence of receptor-specific antagonists. In these experiments, the cells were treated with saturating concentrations of receptor-specific antagonists followed by the addition of receptor agonists and incubation for 20 min prior to BRET measurements. As shown in Figure 4A , agonist-promoted BRET signal was inhibited only in the presence of receptor-specific antagonists. To show that the inhibition of the BRET-β-arrestin2 recruitment correlates well with antagonist affinities measured from radioligand binding assays, we generated dose-response curves with the CCR5 antagonist TAK799 (Fig. 4B) . The derived apparent inhibition activity of TAK799 (appK act~2 .0 nM) agreed well with the affinity of TAK799 for CCR5 (K i = 1.1 nM) that was previously reported from radioligand binding studies. 33 Taken together, the results presented here show that the developed double stable cell lines are suitable to measure and quantify receptor activation and inhibition in a pharmacologically relevant manner.
HTS for antagonists of CCR5 using a BRET1-␤-arrestin2 recruitment assay in stable HEK293 cells
The chemokine receptors CCR5 and CXCR4 are of extreme clinical importance because they are required for HIV-1 entry into the target cell (R5 HIV-1 strains use CCR5 whereas X4 HIV-1 a. BRET1 assays done on agonist-stimulated cells stably coexpressing β-arrestin2-Rluc and GPCR-VENUS are described in the legend of Figures 4B, 4C) . b. EC 50 data were obtained from the references listed.
FIG. 3.
Agonist-promoted β-arrestin2-Rluc recruitment to VENUSfused G protein-coupled receptors (GPCRs). HEK293 cells stably coexpressing β-arrestin2-Rluc and GPCRs-VENUS were seeded at a density of 30,000 cells/well in 96-well white opaque plates followed by BRET1 measurements at room temperature. (A) Association kinetics of agonist-promoted β-arrestin2-Rluc to class A GPCRs (β2AR, V1aR) and class B GPCRs (V2R, CCR5, PAF-R). Real-time bioluminescence resonance energy transfer (BRET) 1 measurements were taken at regular intervals for the indicated period of time directly after the addition of the coelenterazine-h and receptor-specific agonists at saturating concentrations (β2AR, 1 µM isoproterenol; V1aR and V2R, 1 µM AVP; CCR5, 0.1 µM RANTES; PAF-R, 0.1 µM c-PAF). Apparent association constants (t½) were calculated to be 2.7 ± 0.1 min for V2R, 3.0 ± 0.3 min for PAF-R, 2.7 ± 0.4 min for CCR5, 2.4 ± 0.1 min for β2AR, and 1.0 ± 0.1 min for V1aR. (B) Agonist-promoted β-arrestin2-Rluc dose-response curves. Cells were stimulated at room temperature with increasing concentrations of receptor-specific agonists for 30 min (class B receptors: V2R, CCR5, PAF-R) or 5 to 15 min (class A receptors) for V1aR and β2AR, respectively, followed by BRET1 measurements. (C) Agonist-promoted β-arrestin2-Rluc recruitment to CXCR4-VENUS and CXCR4-R5ctail-VENUS. Cells stably coexpressing β-arrestin2-Rluc and CXCR4-VENUS or CXCR4-R5ctail-VENUS were challenged with the CXCR4 receptor agonist SDF1α for 30 min at room temperature followed by BRET1 measurement. Data are mean ± SEM of 3 independent experiments, each done in duplicate. strains use CXCR4; reviewed by Berger et al. 30 ). CCR5 is the coreceptor used by the majority of HIV-1 strains that predominate at early stages of infection, whereas viral entry by CXCR4 is associated more with advanced progression to the clinical stage of the disease. Individuals harboring a nonfunctional form of CCR5 (contains a 32 bp deletion polymorphism; ∆32-CCR5 homozygous genotype) were found to have increased resistance to HIV-1 infection, whereas having no health problems related to this genetic deletion. 51 This indicates that specific CCR5 antagonists could potentially block HIV-1 infection without mechanism-based side effects. Several inhibitors of CCR5, including modified chemokines, 52 monoclonal antibodies to CCR5, 53 and a small molecule antagonist (TAK799), 33 have been shown to inhibit HIV-1 cell entry in vitro. In addition, in vivo inhibition of HIV-1 replication was achieved in a mouse model using a small molecule antagonist (SCH-C) to CCR5. 54 Because CCR5 is a validated anti-HIV-1 entry drug target, we wanted to test whether the developed CCR5-VENUS/β-arrestin2-Rluc HEK293 cell line could serve as an HTS platform for CCR5 antagonists. For HTS purposes, we performed the BRET screening assay on attached cells, thus allowing convenient plate staggering time and ensuring that the cells in each 96-well plate were processed in a similar way. To determine the Z′ score of the assay, we measured the BRET1-β-arrestin2 recruitment in 4 consecutive 96-well plates such that half of each plate received the CCR5 agonist RANTES at 10 nM (~3 × EC 50 of RANTES) or 100 nM (a saturating concentration) and the other half received the agonist vehicle. The individual BRET readings for all the tested wells are shown in Figure 5A . The Z′ scores were 0.61 and 0.8, in presence of 10 nM and 100 nM RANTES, respectively (Fig. 5A) . The Z′ score obtained in the presence of the CCR5-specific antagonist TAK799 (100 nM) and 10 nM of RANTES was determined to be 0.71 (data not shown). This indicated that the BRET-β-arrestin assay for CCR5 is of high quality and suitable for HTS (Z′ score > 0.5). 55 Before committing to screen a large collection of compounds, we tested the assay's signal reproducibility in an antagonist screen of 640 compounds belonging to the MicroSource Discovery natural products collection. The same screen was repeated on a different day, and the derived BRET signals were compared. As shown in Figure 5B , the BRET β-arrestin recruitment signals obtained from screening the same compound collection on 2 different days overlapped well, indicating that the assay was reproducible. We then screened a total of 26,000 compounds for antagonistic activity against RANTES-promoted β-arrestin2 recruitment. To increase throughput, we pooled 2 compounds per well, each at a final concentration of 25 µM, keeping the final DMSO concentration at 0.5%. The primary hit rate of compounds inhibiting the BRET-βarrestin signal by at least 50% (all of them amounting to more than 3 standard deviations of the signal obtained in the presence of the agonist alone) was~2% (note that this hit rate was obtained before deconvolution, i.e., from screening 2 compounds/well). The putative hits were then cherry-picked and individually screened at a final concentration of 10 µM, resulting in a total of 26 confirmed hits BRET1-Based -Arrestin2 Recruitment Assay  FIG. 4 . Antagonist inhibition of β-arrestin-Rluc recruitment to agonist-activated receptors. (A) Cells stably coexpressing β-arrestin2-Rluc and receptor-VENUS were preincubated at room temperature for 5 min with saturating concentration of receptor-specific antagonists (0.1 µM SR12463 for V2R; 0.1 µM CV3998 for PAF-R; 0.1 µM AMD3100 for CXCR4; 10 µM pindolol for β2R; 10 µM PhAc-AVP for V1aR) or with the antagonist vehicle alone, followed by the addition of receptor-specific agonists (1 nM and 100 nM AVP for V2R and V1aR, respectively; 1 nM for PAF-R; 5 nM SDF1α for CXCR4; 1 µM isoproterenol for β2AR). Bioluminescence resonance energy transfer (BRET) 1 measurements were performed 20 min postagonist addition, except for the case of V1aR and β2R, in which BRET1 measurements were done 5 min and 12 min, respectively, after agonist addition. (B) Cells stably coexpressing β-arrestin2-Rluc and CCR5-VENUS were preincubated at room temperature (5 min) with increasing concentrations of the CCR5 antagonist TAK799, followed by the addition of 10 nM RANTES, and BRET1 measurements after 20 min incubation at room temperature.
representing an overall 5% confirmation rate. This relatively low confirmation rate is probably the consequence of several factors. First, when considering that the initial screen was done in duplex (2 compounds per well), the real confirmation rate is more likely to be close to 10%. Second, pooling 2 compounds per well might have increased the chance for compound precipitation, leading to toxic or signal-quenching effects that may have resulted in false positives that were not detected when each compound was tested separately. Finally, and probably most important, is the fact that the confirmation screen was performed at a lower concentration than the primary screen (10 µM vs. 25 µM), especially when consider-ing that the majority of the primary hits were close to the signal cutoff defined for the assay. The use of a higher concentration in the primary round was done with the intention of increasing our chance of having a reasonable number of hits. Upon realizing that the primary hit rate was relatively high, we decided to increase the stringency of our screen by performing the secondary screen at a lower concentration, thus focusing on the more potent hit candidates. To confirm the specificity of these potential CCR5 inhibitors, we tested the effect of these compounds on the BRET-β-arrestin2 agonist-promoted signal in HEK293 cells expressing the V2R-VENUS and β-arrestin2-Rluc. Of the 26 compounds used, 12 were found to be specific only for CCR5 ( Table 2 ) and did not significantly affect the β-arrestin2 recruitment to the V2 receptor. None of the tested compounds were able to promote by themselves β-arrestin2 recruitment to CCR5, indicating that they do not function as CCR5 agonists (data not shown). It is not clear for now whether the compounds that inhibited the BRET-β-arrestin2 recruitment to both CCR5 and V2R ( Table 2 ) mediate their inhibition nonspecifically or whether these compounds might be acting on β-arrestin2-Rluc itself.
We decided to follow up on 3 of the compounds that seemed to be selective for CCR5 and to perform additional confirmatory testing of their anti-CCR5 activity from a resupply of these compounds. We repeated the BRET-β-arrestin2 assays in cells coexpressing β-arrestin2-Rluc and CCR5-VENUS or V2R-VENUS or CXCR4-R5ctail-VENUS, in the presence of increasing concentrations of each compound (0.01-100 µM). Figure 6A shows that the test compounds exhibited a dose-dependent inhibition of the agonist-promoted β-arrestin2 recruitment to CCR5. The calculated apparent inhibition constants were 0.55 ± 0.1 µM, 0.34 ± 0.01 µM, and 0.31 ± 0.07 µM for compounds 446, 693, and 699, respectively. In addition, none of the compounds (even at 100 µM) were able to inhibit β-arrestin2 recruitment to V2R-VENUS or CXCR4-R5ctail-VENUS cells that were stimulated with their respective agonists (AVP, 2 nM for V2R; SDF1α, 10 nM for CXCR4-R5ctail; data not shown). This indicated that the tested compounds are likely specific antagonists of CCR5. The antagonist properties of 446, 693, and 699 were further confirmed by using another functional assay that measures intracellular calcium release upon agonist activation of CCR5. In the calcium flux assay, the CCR5-VENUS stable HEK293 cells were loaded with a calcium-sensitive dye prior to the addition of test compounds and RANTES. A shown in Figure 6B , compounds 446, 693, and 699 acted as antagonists of CCR5 whereby they inhibited RANTESpromoted calcium release without resulting in receptor activation, thus confirming the results obtained with the BRET-β-arrestin2 recruitment assay.
In conclusion, we have described in this study the establishment of a BRET1-β-arrestin2 recruitment assay in stable cell lines for several GPCRs and its use for the first time in HTS for CCR5 antagonists. The development of stable cell lines coexpressing optimal amounts of the receptor-VENUS and β-arrestin2-Rluc greatly simplifies its use for HTS, circumventing the need for transient Cells stably coexpressing β-arrestin2-Rluc and CCR5-VENUS were seeded in white opaque tissue culture 96-well plates at a density of 15,000 cells/well. The next day, bioluminescence resonance energy transfer (BRET) 1 measurements were done on attached cells in the presence or absence of RANTES (10 nM and 100 nM), as described under the HTS method section. In total, 4 consecutive 96-well plates were processed such that each half-plate received agonist vehicle (basal BRET) and the other half received agonist treatment. Z′ scores were calculated using the following formula 55 : Z′ = 1 -[3 × SD(agonist) + 3 × SD(basal)]/ (BRETagonist -BRETbasal), where SD = standard deviation. Data shown are representative of 2 independent experiments. (B) BRET signal reproducibility in an antagonist screen. Six hundred forty compounds were screened on 2 different days for inhibition of RANTES-induced β-arrestin2-Rluc recruitment to CCR5-VENUS, as described in the Materials and Methods section. The BRET1 signals from the duplicate screens done on different days were normalized to 1 (1 being BRET signal in presence of agonist alone). transfections that require continuous optimization/controlling and are more prone to day-to-day variability. We also employed the use of C-tail swapping between GPCRs, as for the case of CXCR4 containing the C-tail of CCR5, as a potential strategy to improve the BRET-β-arrestin2 signal of some receptors to a level that is suitable for assay screenings. The BRET-β-arrestin2 assay holds many advantages over other cell-based assays for GPCR activation: 1) the BRET-β-arrestin assay is independent of the G proteincoupling preference of the receptor, which makes it applicable to most GPCRs that internalize via the β-arrestin pathway; 2) the assay requires minimal manipulation, and the instrumentation and reagents needed for reading the signal are relatively inexpensive; 3) the assay is easily quantifiable, having a ratiometric readout that is not affected by variations in cell number; and 4) the assay is luminescence based, which avoids the problems associated with fluorescence-based assays (photobleaching, autofluorescence). Taken together, the data presented here provide the first proof of principle that BRET1 in general, and the BRET1-β-arrestin2 recruitment assay in particular, can be used for HTS campaigns in living mammalian cells.
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Journal of Biomolecular Screening 10(5); 2005 www.sbsonline.org 473 BRET = bioluminescence resonance energy transfer; HTS = high-throughput screening. Cells stably coexpressing β-arrestin2-Rluc and CCR5-VENUS or β-arrestin2-Rluc and V2R-VENUS were preincubated with various test compounds (10 µM) for 10 min at room temperature, followed by the addition of the receptor-specific agonists (10 nM RANTES for CCR5; 2 nM AVP for V2R). BRET1 measurements were taken 30 min postagonist addition, and the values were normalized to 1 (signal obtained in the presence of the agonist alone).
FIG. 6.
Inhibition of CCR5 activity by compounds 446, 693, and 699. (A) Dose-dependent inhibition of β-arrestin2 recruitment to CCR5. HEK293 cells stably coexpressing CCR5-VENUS and β-arrestin2-Rluc were preincubated for 10 min at room temperature with various concentrations of test compounds, followed by the addition of RANTES (10 nM final) and an incubation period of 30 min. Bioluminescence resonance energy transfer (BRET) was then measured on the FUSION as described in the Materials and Methods section. Data are presented as the percentage of BRET signal obtained in the presence of RANTES alone. (B) Compounds 446, 693, and 699 inhibit RANTES-induced calcium flux but do not induce themselves calcium mobilization. Test compounds (10 µM final) were added to cells stably expressing CCR5-VENUS that had been loaded with a calcium-sensitive reagent dye, and fluorescence measurements were done prior and after the addition of RANTES (10 nM), as described in the Materials and Methods section. Data are presented as percentage of fluorescence signal obtained in the presence of RANTES alone (~30,000 relative fluorescence units above background). Data shown in this figure are averages mean ± SEM of 3 independent experiments, each done in duplicate.
